Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Genitourinary tumours, prostate

1082 - Randomized Controlled Trial Comparing Radiotherapy +/- Endocrine Therapy Versus Endocrine Therapy Alone for PSA Failure after Radical Prostatectomy: Japan Clinical Oncology Group Study JCOG0401


10 Sep 2017


Genitourinary tumours, prostate


Cytotoxic Therapy;  Surgical Oncology;  Radiation Oncology;  Prostate Cancer


Akira Yokomizo


Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370


A. Yokomizo1, T. Satoh2, K. Hashine3, T. Inoue4, K. Fujimoto5, S. Egawa6, T. Habuchi7, K. Kawashima8, O. Ishizuka9, N. Shinohara10, M. Sugimoto11, Y. Yoshino12, M. Wakabayashi13, K. Nihei14, H. Fukuda13, K. Tobisu15, Y. Kakehi11, S. Naito1

Author affiliations

  • 1 Urology, Harasanshin Hospital, 812-0033 - FUKUOKA/JP
  • 2 Urology, Kitasato University School of Medicine, Sagamihara/JP
  • 3 Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama/JP
  • 4 Urology, Kyoto University Hospital, Kyoto/JP
  • 5 Urology, Nara Medical University, Nara/JP
  • 6 Urology, Jikei University Hospital, Tokyo/JP
  • 7 Urology, Akita University Graduate School of Medicine, Akita/JP
  • 8 Urology, Tochigi Cancer Center, Utsunomiya/JP
  • 9 Urology, Shinshu University School of Medicine, Matsumoto/JP
  • 10 Renal And Genitourinary Surgery, Hokkaido University Hospital, Sapporo/JP
  • 11 Urology, Faculty of Medicine, Kagawa University, 761-0793 - Kagawa/JP
  • 12 Urology, Nagoya University Graduate School of Medicine, Nagoya/JP
  • 13 Jcog Data Center/operations Office, National Cancer Center, Tokyo/JP
  • 14 Division Of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo/JP
  • 15 Urology, Tokyo Metropolitan Cancer and Infectious disease Center Komagome Hospital, Tokyo/JP


Abstract 1082


A standard therapy has not been established on PSA failure after radical prostatectomy for localized prostate cancer. Therefore, the randomized controlled trial was designed to confirm the superiority of radiotherapy ± endocrine therapy over endocrine therapy alone for PSA failure after radical prostatectomy.


Patients were randomly assigned to arm A [endocrine therapy only: bicalutamide (BCL) monotherapy followed by LH-RH agonist in case of BCL failure], or arm B [64.8 Gy of salvage radiotherapy (SRT) followed by same regimen of arm A in case of treatment failure of SRT]. The primary endpoint is time to treatment failure (TTF) of BCL, and secondary endpoints are TTF of protocol treatment, clinical relapse-free survival (RFS), overall survival (OS), adverse events. The planned sample size was 210 to detect improvement of median TTF of BCL from 5 years to 8.3 years with one-sided alpha of 5% and power of 80%. This trial is registered with UMIN-CTR (C000000026).


A total of 210 patients (105 patients in each arm) were registered from May 2004 to May 2011. The TTF of BCL was significantly better in arm B as shown in Table 1 (Hazard ratio 0.56 90% CI (0.40–0.77); one-sided p = 0.001). The 33 patients (32%) of 102 patients with SRT of arm B had no treatment failure of SRT, resulting in being free from hormonal therapy. In addition, TTF of protocol treatment was also significantly better in arm B. However, clinical RFS and OS were similar between the arms. Grade 4 adverse event was reported in one patient in arm B.Table:


Arm AArm BHazard Ratio (95% CI)
(endocrine therapy only) (95% CI)(radiation +/- endocrine therapy) (95% CI)
5-year TTF of BCL57.0% (46.7%–66.0%)69.7% (59.6%–77.7%)0.56 (0.38-0.82)
5-year TTF of protocol treatment67.0% (56.9%–75.3%)76.8% (67.1%–83.9%)0.66 (0.44-1.00)
5-year clinical RFS93.8% (86.8%–97.2%)88.9% (80.9%–93.7%)0.90 (0.45-1.81)
5-year OS99.0% (93.4%–99.9%)91.4% (84.2%–95.4%)1.03 (0.46-2.29)


The first SRT had advantage in both TTF of BCL and protocol treatment. Although the clinical outcomes of both arms of salvage therapy were similar with each other in terms of clinical PFS and OS, the SRT was effective in 32% of the patients, which contributed to avoiding the salvage endocrine therapy.

Clinical trial identification

UMIN-CTR (C000000026)

Legal entity responsible for the study

Japan Clinical Oncology Group, JCOG


Ministry of Health, Labor and Welfare of Japan


A. Yokomizo: Lecture fee from Astellas Pharma Inc., AstraZeneca K.K.and Takeda Pharmaceutical Company Limited. T. Satoh: lecture fee from Bayer AG, Astellas Pharma Inc., and AstraZeneca K.K. K. Hashine: lecture fee from Astellas Pharma Inc., Sanofi, Takeda Phrmaceutical Co.Ltd., Brystol Myers, AstraZeneca and Janssen Pharma. T. Inoue: lecture fee from Astellas Pharma Inc., AstraZeneca K.K.and Janssen Pharma K.K. K. Fujimoto: lecture fee from AstraZeneca K.K.and Takeda Pharmaceutical Company Limited S. Egawa: AstraZeneca, Astellas, Takeda Pharma Co. O. Ishizuka: Research grant from Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Pfizar Japan Inc. Lecture fee from Astellas Pharma Inc. N. Shinohara: Lecture fee from Bayer Co., Astellas Pharma Inc., Pfizer, and Novartis. .Advisary fee from Ono Pharma Inc. and Takeda Pharma. Co. S. Naito: Personal financial interest from Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd. and Green Peptide Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.